204 related articles for article (PubMed ID: 25794458)
1. Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death.
Gerdtsson A; Poon JB; Thorek DL; Mucci LA; Evans MJ; Scardino P; Abrahamsson PA; Nilsson P; Manjer J; Bjartell A; Malm J; Vickers A; Freedland SJ; Lilja H; Ulmert D
Eur Urol; 2015 Dec; 68(6):1076-82. PubMed ID: 25794458
[TBL] [Abstract][Full Text] [Related]
2. Towards an optimal interval for prostate cancer screening.
van Leeuwen PJ; Roobol MJ; Kranse R; Zappa M; Carlsson S; Bul M; Zhu X; Bangma CH; Schröder FH; Hugosson J
Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
[TBL] [Abstract][Full Text] [Related]
3. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
4. Metformin use and prostate cancer risk.
Preston MA; Riis AH; Ehrenstein V; Breau RH; Batista JL; Olumi AF; Mucci LA; Adami HO; Sørensen HT
Eur Urol; 2014 Dec; 66(6):1012-20. PubMed ID: 24857538
[TBL] [Abstract][Full Text] [Related]
5. Association of serum lipid levels and prostate cancer severity among Hispanic Puerto Rican men.
Salgado-Montilla J; Soto Salgado M; Surillo Trautmann B; Sánchez-Ortiz R; Irizarry-Ramírez M
Lipids Health Dis; 2015 Sep; 14():111. PubMed ID: 26377420
[TBL] [Abstract][Full Text] [Related]
6. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.
Grytli HH; Fagerland MW; Fosså SD; Taskén KA
Eur Urol; 2014 Mar; 65(3):635-41. PubMed ID: 23351721
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Eur Urol; 2014 Jan; 65(1):177-85. PubMed ID: 22981136
[TBL] [Abstract][Full Text] [Related]
8. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.
Akre O; Garmo H; Adolfsson J; Lambe M; Bratt O; Stattin P
Eur Urol; 2011 Sep; 60(3):554-63. PubMed ID: 21664039
[TBL] [Abstract][Full Text] [Related]
9. Physical Activity and Survival After Prostate Cancer.
Friedenreich CM; Wang Q; Neilson HK; Kopciuk KA; McGregor SE; Courneya KS
Eur Urol; 2016 Oct; 70(4):576-585. PubMed ID: 26774959
[TBL] [Abstract][Full Text] [Related]
10. Waist circumference, waist-hip ratio, body mass index, and prostate cancer risk: results from the North-American case-control study Prostate Cancer & Environment Study.
Boehm K; Sun M; Larcher A; Blanc-Lapierre A; Schiffmann J; Graefen M; Sosa J; Saad F; Parent MÉ; Karakiewicz PI
Urol Oncol; 2015 Nov; 33(11):494.e1-7. PubMed ID: 26278366
[TBL] [Abstract][Full Text] [Related]
11. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort.
Bhindi B; Locke J; Alibhai SMH; Kulkarni GS; Margel DS; Hamilton RJ; Finelli A; Trachtenberg J; Zlotta AR; Toi A; Hersey KM; Evans A; van der Kwast TH; Fleshner NE
Eur Urol; 2015 Jan; 67(1):64-70. PubMed ID: 24568896
[TBL] [Abstract][Full Text] [Related]
12. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men.
Gong Z; Agalliu I; Lin DW; Stanford JL; Kristal AR
Cancer; 2007 Mar; 109(6):1192-202. PubMed ID: 17311344
[TBL] [Abstract][Full Text] [Related]
13. Natural history of early, localized prostate cancer: a final report from three decades of follow-up.
Popiolek M; Rider JR; Andrén O; Andersson SO; Holmberg L; Adami HO; Johansson JE
Eur Urol; 2013 Mar; 63(3):428-35. PubMed ID: 23084329
[TBL] [Abstract][Full Text] [Related]
14. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly.
Bhindi B; Kulkarni GS; Finelli A; Alibhai SM; Hamilton RJ; Toi A; van der Kwast TH; Evans A; Hersey K; Jewett MA; Zlotta AR; Trachtenberg J; Fleshner NE
Eur Urol; 2014 Nov; 66(5):841-8. PubMed ID: 24954793
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population.
Orsted DD; Nordestgaard BG; Jensen GB; Schnohr P; Bojesen SE
Eur Urol; 2012 May; 61(5):865-74. PubMed ID: 22104593
[TBL] [Abstract][Full Text] [Related]
16. Lifetime body size and prostate cancer risk in a population-based case-control study in Sweden.
Möller E; Adami HO; Mucci LA; Lundholm C; Bellocco R; Johansson JE; Grönberg H; Bälter K
Cancer Causes Control; 2013 Dec; 24(12):2143-55. PubMed ID: 24048969
[TBL] [Abstract][Full Text] [Related]
17. The impact of interscreening interval and age on prostate cancer screening with prostate-specific antigen.
Wu GH; Auvinen A; Yen AM; Hakama M; Tammela TL; Stenman UH; Kujala P; Ruutu M; Chen HH
Eur Urol; 2012 May; 61(5):1011-8. PubMed ID: 22264679
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
van Leeuwen PJ; Connolly D; Gavin A; Roobol MJ; Black A; Bangma CH; Schröder FH
Eur J Cancer; 2010 Jan; 46(2):377-83. PubMed ID: 19804966
[TBL] [Abstract][Full Text] [Related]
19. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
20. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
